The C-peptide, which consists of the connecting segment of proinsulin minus the basic resides at each end, is a product of proinsulin processing that is stored and cosecreted with insulin in essentially equimolar amounts from the beta cell. It has been isolated from the pancreas of man and a number of other species and studies of its secretion and metabolic clearance have established that it is a valuable and reliable indicator of beta-cell secretory function in normal and diabetic subjects. Unlike insulin, which is rapidly removed from the circulation by receptor binding, the C-peptide has a prolonged half-life without significant tissue sequestration. In mammals the C-peptide ranges in length from 26-31 residues, has a 15-fold greater rate of mutation acceptance than insulin and is cleaved internally prior to secretion in some species, i.e., the dog, fox and others. It has a somewhat restricted composition, notable for the absence of aromatic residues, and usually contains four or five acidic residues, which offset the four basic amino acids at the cleavage sites thus maintaining a very similar isoelectric point in proinsulin to that of insulin. The foremost biosynthetic role of the C-peptide clearly is to serve as a flexible linker between the insulin B and A chains so as to facilitate the proper folding of the peptide chain and disulfide bond formation. The C-peptide does this mainly by converting the bimolecular reaction of chain combination to a more efficient monomolecular reaction, but this function can also be accomplished by much shorter or even totally deleted connecting segments. The strong conservation of the length of the C-peptide in evolution, however, is consistent with the requirement for its efficient excision from proinsulin during its conversion to insulin; experiments with truncated C-peptides show marked reductions in conversion efficiency. Optimal binding of proinsulin to the prohormone convertases for cleavage imposes significant constraints on the length and.properties of the C-peptide, as will be discussed. Moreover, the C-peptide may play a role in sorting and must be compatible with other constituents of the secretory granule in which it is stored, e.g., insulin, islet amyloid peptide and others. In addition to these constraints, the mammalian C-peptides may have acquired some additional beneficial functions that complement insulin action.
The observation in 1992 that C-peptide in physiological concentrations can correct glomerular hyperfiltration and increase renal blood flow in patients with type 1 diabetes [11 became the starting point for continued studies of C-peptide physiology in Stockholm These findings sub-sequently led to more detailed studies of renal function in diabetes, evaluation of C-peptide-blood flow interactions, studies of C-peptide's cellular interactions and signal transduction, and investigations of C-peptide and nerve function in diabetes.
The initially observed C-peptide effect on renal function has been confirmed and extended in both experimental studies in streptocotozin-diabetic (STZ) rats and type 1 diabetes patients. Thus, C-peptide replacement for periods of two weeks to three months in animals and patients with early nephropathy results in diminished glomerular hyperfiltration and reduced urinary albumin excretion. [2] [3] [4] The effect of C-peptide on blood flow has been further examined using the forearm model in type 1 diabetes patients. A significant increase in forearm blood flow is observed during i.v., infusion of C-peptide in the resting state. [51 Likewise, infusion of C-peptide during rhythmic forearm exercise results in a marked increase in both blood flow and oxygen uptake. [6] The latter finding prompted an evaluation of C-peptide's possible influence on Na+, K+-ATPase. It could be shown that C-peptide has the capacity to stimulate renal tubular cell Na+, K+-ATPase activity in a concentration-dependent manner, probably by activating a receptor coupled to a pertussis-toxin sensitive G-protein with subsequent acti- It has been suggested that C-peptide effects may be mediated by non-chiral cell membrane interactions similar to those of antimicrobial peptides. [9] However, there is now new evidence that C-peptide binds to specific cell surface receptors which has been obtained using fluorescence correlation spectroscopy. Specific binding of human C-peptide could be demonstrated for human tubular cells, skin fibroblasts and saphenous venous endothelial cell. [ 11 Kas for C-peptide binding was 3.10 -9 M-1. Insulin, IGF and II, proinsulin and NPY showed no cross-reactivity. The C-peptide binding isotherm'indicates that half saturation is reached at approximately 0.9nM. This finding explains the consistent observation that no effects of C-peptide can be observed in healthy individuals or animals, in whom the ambient C-peptide concentration will be sufficient to cause saturation of C-peptide receptors.
Reduced levels of endoneurial Na+, K+-ATPase and diminished blood flow have been reported in diabetes. The effect of C-peptide on motor nerve conduction velocity [9] The development of single molecule detection and fluorescence correlation spectroscopy (FCS) [1] has provided the tools to analyze the interaction between fluorescently tagged ligands and their specific targets. We have been able to show that tetramethylrhodamin labelled C-peptide is able to bind specifically to receptors at the cell membrane. From, the study of the Brownian motion of C-peptide receptor complexes we were able to show [2, 31 (i) a high affinity binding of the C-peptide to the receptor, (ii) a high specificity of the interaction which is related to a C-terminal pentapeptide sequence. Furthermore the data obtained from studies where the function of G-proteins was inhibited by pertussis toxin and a significant change of the binding affinity was found, suggest the existence of an allosteric network involving receptor conformations with different affinities to both C-peptide as well as G-protein.
Recent developments of 3 dimensional imaging of the C-peptide receptor complex in living cells and the simultaneous analysis of the Brownian mobility provides new insights in the functional activity of the C-peptide.
Observations of clinical effects Of C-peptide in patients with diabetes type I, [1] combined with measurable effects of C-peptide and its fragments on cellular Na + K + ATPase activity, [2, One of the early findings of C-peptide's effect in type I diabetes was its ability to reduce the glomerular filtration rate, increase renal blood flow and reduce the renal filtration fraction. Ill It was hypothesized that C-peptide may cause a reduction in capillary leakage, possibly by an increase in capillary recruitment. It had b, een described previously that diabetic patients have an increased vascular permeability. [2] To examine C-peptide s possible effect on vascular permeability, IDDM patients were studied during rhythmic forearm exercise. TM It was found that both forearm blood flow and capillary diffusion capacity (CDC) increased during C-peptide replacement (+ 27 + 4%, p < 0.001 and 52 9%, p < 0.01, respectively) and vascular resistance decreased to levels similar to those found in healthy control subjects. The technique used did not allow a conclusion as to whether CDC was increased due to altered capillary recruitment and/or permeability. It was shown in a subsequent study using the perfused rat hindquarter model that C-peptide has no effect on vascular permeability but stimulates capillary recruitment. [41 C-peptide exerts a stimulatory effect on forearm blood flow also in the resting state. In a recent study in Stockholm the concentration-dependent effect of C-peptide on forearm blood flow was examined in 12 IDDM patients in a placebo-controlled, double-blind study using venous occlusion plethysmography, a technique for the measurement of total blood flow in a forearm segment. It could be demonstrated that a low dose of C-peptide (1 pmol/kg/min) resulting in a plasma C-peptide level of ---0.2 nM significantly increased forearm blood flow with 15% above basal. When the C-peptide concentration was increased to ---1 nM by a higher infusion rate (5 pmol/kg/min, the dose previously used in all of the above studies) blood flow was increased by 25%. However, with an even higher dose (25 pmol/kg/min) resulting in a C-peptide concentration of ---7 nM, a significantly higher blood flow was not found.
This was in accordance with previous findings by Johansson and Pernow 1999 [sl where basal forearm blood flow was stimulated by C-peptide (5 pmol/kg/min) in IDDM patients (+25 6%, p < 0.01). In that study it was also confirmed that increased blood flow was associated with a decreased vascular resistance (-17 + 5%, p < 0.01).
To examine C-peptide's effect on endothelial function of the larger arteries in type 1 diabetes, Johansson and colleagues [61 determined blood flow velocity and brachial artery diameter responses following reactive hyperemia (RH) and administration of glyceryl trinitrate (GTN) using high-resolution ultrasound technology. They found that the shear stress induced arterial dilatation following RH was impaired in the diabetes patients (diabetics 2% vs. controls 9%), whereas the response to GTN was normal. Following C-peptide administration the basal blood flow velocity in the brachial artery was increased by 26%, p < 0.05, but the responses to RH and GTN were unaltered. This suggests that C-peptide acts primarily on resistance arterial vessels.
As to the mechanism for C-peptide action on blood flow, it has been demonstrated in bovine aortic endothelial cells that C-peptide stimulates on the endothelial nitric oxide synthase (eNOS) activity, resulting in an increased NO production. [71 The C-peptide induced NO release was abolished by addition of a NOS inhibitor. Recently, this was also tested in humans; intra-arterial administration of C-peptide to type 1 diabetes patients resulted in an immediate blood flow response (---30%) and when C-peptide was co-administered with L-NMMA (a NOS inhibitor) the stimulatory effect of C-peptide was abolished. [8] In conclusion, the available data indicate that in type I diabetes C-peptide stimulates eNOS and release of NO primarily at the level of the resistance vessels, resulting in ihcreased blood flow, decreased vascular resistance and increased capillary recruitment. C-peptide's effect is concentration-dependent in the range of 0-1 nM. The stimulatory effect of C-peptide may be beneficial in the prevention of diabetic complications. diabetic BB/Wor-rats were started on the same C-peptide treatment continued to 8 mo of diabetes (intervention group (IG)). In the PG the NCD was significantly decreased (p < 0.001) compared to untreated BB/Wor-rats and was similar to that of normo-C-peptidemic and isohyperglycemic type 2 BBZ rats. This effect was associated with significant preventions of nodal changes (p < 0.001) including axo-glial dysjunction (p < 0.001), which was not different from non-diabetic control rats. Axonal atrophy and Wallerian degeneration were significantly prevented (both p < 0.05). In the IG the NCD decreased significantly (p < 0.01) during the 3 mo treatment period. Associ Short-term infusion (140 min) of C-peptide in STZ-treated animals was found to diminish GFR, reduce renal protein leakage and augment the renal functional reserve. [1] Subsequent studies involving C-peptide infusion for 14 days in rats with experimental diabetes not only confirmed the results with regard to reduction in GFR and diminished albumin excretion but also demonstrated markedly reduced renal structural changes, as evidenced by reduced glomerular hypertrophy. [21 The above results in diabetic animals have been borne out in studies involving patients with type I diabetes and mild diabetic nephropathy. Thus, i.v., infusion of human C-peptide (2 h) was found to be accompanied by a significant reduction of GFR (7%) and a small rise in renal blood flow (3%). [3] During more prolonged C-peptide administration (4 weeks) in type 1 patients (n 9), provided by subcutaneous continuous rate infusion, it could be shown that both GFR and urinary albumin excretion decreased significantly, indicating a beneficial effect on glomerular permeability in type 1 diabetes. [4] However, in this study glycemic control tended to improve in the C-peptide treated group but not in the controls. This raised the question of whether the observed improvement in renal function represented a direct C-peptide effect or if it was a secondary effect related to the amelioration of blood glucose control. Therefore, a larger study was undertaken involving 22 type 1 diabetic patients with microalbuminuria receiving human C-peptide in doses calculated to restore the physiological concentration for 3 months in a doubleblind randomized cross-over design. In this study glycemic control was not different during C-peptide and placebo treatment, respectively. The results showed a statistically significant, substantial reduction in microalbuminuria (40%) during C-peptide administration and no significant change during placebo treatment. [51 The mechanism underlying the diminished albumin excretion during C-peptide administration is not known. It is possible, however, that C-peptide may exert a direct effect on the glomerular handling of albumin, as suggested from the studies of renal function in streptozotocin induced diabetic rats. A blunted Na+, K+-ATPase activity has been shown in animals and humans with diabetic mellitus, especially in renal and nerve tissue. It has been found that C-peptide exerts a concentration dependent stimulatory effect on Na+, K+-ATPase activity in rat renal tubular cells. Similar findings have also been obtained in glomeruli from streptozoto-cin-induced diabetic rats. Finall,y evidence is now available, indicating that C-peptide may stimulate endothelial nitric oxide synthase. [61 In this context it is of interest that specific binding of C-peptide to membrane-bound receptors has [7] been demonstrated in the nanomolar concentration range for renal cells. Thus, it may be hypothesized that Cpeptide has the potential to influence membrane permeability and transport as well as stimulate regional blood flow, possibly resulting in improvements in renal function in the diabetic state.
In conclusion, the combined animal experiment and human trial data demonstrate that C-peptide replacement in type I diabetes and mild nephropathy exerts a beneficial effect on renal structure and function. The possibility should be considered that C-peptide should be provided .to type 1 diabetes patients to prevent or retard the development of diabetic nephropathy.
insulin-stimulated metabolic responses has not been reported. In this study we have investigated the putative role of one Grb10 variant in insulin-induced metabolism with several independent experimental approaches.
We found that over-expression of complete Grbl0 cDNA in Rat 1 fibroblasts over-expressing insulin receptors or in Rat L6 myocytes stimulated insulin-induced cellular responses including glycogen, synthesis, glucose uptake, amino acid uptake and lipogenesis consistent with a role of Grbl0 in insulin-induced metabolism. In contrast, putatively dominant-negative cell membrane-permeable Grbl0 SH2 and Pro-rich domain fusion peptides substantially inhibit insulin-stimulated glycogen synthesis which indicated a role of these domains in insulin-regulated metabolism, consistent with a stimulatory role of complete Grbl0. Association 
